Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spruce Biosciences ( (SPRB) ) has provided an update.
On October 7, 2025, Spruce Biosciences entered into a Securities Purchase Agreement with institutional investors to raise approximately $50 million through a private placement. This transaction involves the sale of common stock and pre-funded warrants, with the closing expected around October 9, 2025. The funds will support the company’s operations, including its efforts to advance therapies for rare diseases, potentially strengthening its market position and impacting stakeholders.
The most recent analyst rating on (SPRB) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.
Spark’s Take on SPRB Stock
According to Spark, TipRanks’ AI Analyst, SPRB is a Underperform.
Spruce Biosciences faces substantial financial challenges with declining revenues and persistent losses. Bearish technical indicators and unfavorable valuation metrics further weigh on the stock. The strategic acquisition of TA-ERT offers potential growth, but the financial instability remains a critical concern.
To see Spark’s full report on SPRB stock, click here.
More about Spruce Biosciences
Spruce Biosciences operates in the biotechnology industry, focusing on developing therapies for rare diseases. The company is advancing tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B, with plans for a biologics license application submission in early 2026 and a potential U.S. commercial launch later that year.
Average Trading Volume: 431,420
Technical Sentiment Signal: Buy
Current Market Cap: $73.42M
Learn more about SPRB stock on TipRanks’ Stock Analysis page.